Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

MBX Biosciences (MBX) Enterprise Value (2024 - 2026)

MBX Biosciences has reported Enterprise Value over the past 4 years, most recently at -$440.0 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$440.0 million for Q1 2026, down 82.73% from a year ago — trailing twelve months through Mar 2026 was -$440.0 million (down 82.73% YoY), and the annual figure for FY2025 was -$373.7 million, down 42.55%.
  • Enterprise Value reached -$440.0 million in Q1 2026 per MBX's latest filing, down from -$373.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $115.9 million in Q3 2023 and bottomed at -$440.0 million in Q1 2026.
  • Median Enterprise Value over the past 4 years was -$240.8 million (2025), compared with a mean of -$180.6 million.
  • The largest annual shift saw Enterprise Value tumbled 845.16% in 2024 before it crashed 41.37% in 2025.
  • Over 4 years, Enterprise Value stood at $35.2 million in 2023, then crashed by 845.16% to -$262.1 million in 2024, then tumbled by 42.55% to -$373.7 million in 2025, then decreased by 17.73% to -$440.0 million in 2026.
  • Business Quant data shows Enterprise Value for MBX at -$440.0 million in Q1 2026, -$373.7 million in Q4 2025, and -$391.7 million in Q3 2025.